ReviewClinical and translational radiation oncology2026
Radiotherapy for Primary Urethral Carcinoma (PUC): An Illustrative and Narrative Review.
Review in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary urethral carcinoma (PUC) is a rare malignancy with a complex and site-specific management paradigm. While surgery remains the mainstay for many cases, advances in modern radiotherapy have facilitated organ preservation without compromising oncologic outcomes. This narrative review outlines the clinicopathological features, diagnostic evaluation, and evolving role of radiotherapy in the management of PUC. An illustrative case of a young male with high-grade urothelial carcinoma of the bulbar urethra managed successfully with definitive external beam radiotherapy is presented. We explore the rationale, technique, and outcomes associated with radiotherapy, including external beam and brachytherapy modalities, across disease stages. For locally advanced cases, chemoradiotherapy offers an organ-sparing alternative to mutilating surgery, with promising control rates and acceptable toxicity. This article aims to collate current evidence, highlight gaps, and support the integration of personalised, multidisciplinary care in this rare disease context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.